Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus KELNOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus KELNOR.
BLISOVI FE 1.5/30 vs KELNOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive